Project Grant F30DA058525

Award Date 6/26/24
Completion Date 12/31/26
Dollars Obligated $211K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The study aims to: 1) characterize real-world trajectories of OUD treatment in the year following hospital encounters among treatment-naive individuals and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...
The Massachusetts General Hospital (MGH) Substance Use Disorder Initiative is a $749,939 Project Grant awarded by the U.S. Department of Justice Office of Juvenile Justice and Delinquency Prevention under the Opioid Affected Youth Initiative (CFDA 16.842). The initiative will provide multidisciplinary, trauma-informed, dyadic-based, longitudinal medical and mental healthcare at MGH's HOPE Clinic, aimed at reducing the intergenerational transmission of substance use and minimizing future juvenile...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,236 to The Washington University to conduct research focused on disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The key objectives of the 5-year project are to: 1) evaluate how race and racial segregation are associated with the use of buprenorphine and methadone as well...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $541,080 to The Trustees of Columbia University in the City of New York to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine versus sublingual buprenorphine/naloxone in treating opioid use disorder (OUD) among individuals who use high-potency synthetic opioids. The key objectives are to compare abstinence and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $1,377,306 multi-jurisdictional study to transform the evidence base on the prevalence of opioid use disorder (OUD) and the impact of opioid agonist treatment (OAT) as a strategy to prevent opioid-related deaths. The study, titled "TRANSFORM - Transforming the Evidence Base on Estimating Prevalence of Opioid Use Disorder and Expanded Access...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is intended to investigate whether a pharmacist-integrated model of opioid use disorder (OUD) treatment can increase naloxone co-prescribing in primary care. The $193,336 award to Trustees of Dartmouth College will fund a research project with three aims: (1) describing federal, state, and clinic-level policies and OUD interventions impacting...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), totaling $444,826, is focused on adapting and testing an innovative, trauma-informed intervention to reduce overdose risk among women re-entering the community from prison. The key activities include: 1) Adapting the Trust-Based Relational Intervention (TBRI) approach by engaging stakeholders to align it with the unique needs of justice-involved women,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is intended to develop and evaluate the efficacy of a universal overdose prevention intervention to be delivered in primary care settings. The $2,467,574 award will fund a pilot two-arm cluster randomized controlled trial at Boston Medical Center to assess the acceptability and feasibility of the intervention for providers and youth ages 13-26. The...

IMPLEMENTATION OF MEDICATIONS FOR OPIOID USE DISORDER IN MASSACHUSETTS JAILS - PROJECT SUMMARY: OPIOID OVERDOSE DEATHS AND OTHER SUBSTANCE-RELATED MORTALITY REMAIN AT AN ALL-TIME HIGH IN THE UNITED STATES, AND EVIDENCE SUGGESTS THAT MORTALITY WILL CONTINUE TO WORSEN WITHOUT SIGNIFICANT CHANGES TO THE LANDSCAPE OF OPIOID USE DISORDER (OUD) TREATMENT. OVERDOSE MORTALITY IS THE LEADING CAUSE OF DEATH IN THE FIRST TWO WEEKS POST-RELEASE DUE TO A VARIETY OF FACTORS INCLUDING CHANGES IN DRUG TOLERANCE DURING INCARCERATION AND VOLATILITY OF THE ILLICIT DRUG SUPPLY, LEADING TO A MORE THAN 100-FOLD INCREASED RISK OF OVERDOSE DEATH COMPARED TO THE NONINCARCERATED POPULATION DURING THIS PERIOD. DESPITE ADVANCES IN ADDICTION HEALTH SERVICES AND CLINICAL ADDICTION MEDICINE, MANY PEOPLE WITH OUD DO NOT HAVE ACCESS TO HEALTHCARE OR MEDICATIONS FOR OPIOID USE DISORDER (MOUD) TREATMENT, WHICH REMAIN THE MOST EFFECTIVE TREATMENT STRATEGIES TO REDUCE OUD- RELATED MORTALITY. CORRECTIONAL FACILITIES SUCH AS JAILS ARE A CRITICAL HEALTHCARE ACCESS POINT FOR PEOPLE WITH OUD WHO MAY NOT RECEIVE HEALTHCARE IN OTHER SETTINGS. HOWEVER, MOUD TREATMENT AVAILABILITY IN JAILS IS HIGHLY VARIABLE ACROSS THE UNITED STATES, LEAVING MANY PEOPLE WITH OUD WITHOUT ACCESS TO EVIDENCE-BASED TREATMENT WHILE INCARCERATED. IMPLEMENTATION OF MOUD TREATMENT IN JAILS IS CRITICAL TO IMPROVE ACCESSIBILITY OF MOUD TREATMENT AND REDUCE OUD-RELATED MORTALITY IN THIS VULNERABLE POPULATION. THERE IS NEED FOR FURTHER RESEARCH ELUCIDATING STRATEGIES THAT LEAD TO SUCCESSFUL AND SUSTAINED IMPLEMENTATION OF MOUD IN JAILS AND OTHER CORRECTIONAL SETTINGS. THIS PROPOSAL USES A MIXED-METHODS APPROACH TO ANALYZE IMPLEMENTATION OF MOUD FROM MULTIPLE PERSPECTIVES. THE PROPOSAL UTILIZES DATA FROM THE MASSACHUSETTS JUSTICE COMMUNITY OPIOID INNOVATION NETWORK (MASSJCOIN) STUDY, A TYPE 1 HYBRID EFFECTIVENESS-IMPLEMENTATION STUDY OF MA CHAPTER 208, WHICH ESTABLISHED A PILOT PROGRAM TO EXPAND ALL FDA-APPROVED FORMS OF MOUD IN MA COUNTY JAILS. AIM 1 WILL QUALITATIVELY ASSESS ORGANIZATIONAL FACTORS RELATED TO MOUD IMPLEMENTATION IN JAILS AND POST-RELEASE OVERDOSE RISK THROUGH THEMATIC ANALYSIS OF INTERVIEWS WITH JAIL STAFF AND PEOPLE WHO RECEIVED MOUD WHILE INCARCERATED IN MA JAILS. AIM 2 WILL INVESTIGATE THE ASSOCIATION BETWEEN STAFF PERSPECTIVES OF MOUD AND ORGANIZATIONAL FACTORS SUCH AS STAFF TRAINING AND READINESS FOR CHANGE. AIM 3 WILL COMPARE MOUD RETENTION OUTCOMES FOR PEOPLE WHO SCREENED POSITIVE FOR OUD WHILE INCARCERATED BETWEEN DIFFERENT TYPES OF MOUD TREATMENT USING THE PUBLIC HEALTH DATA (PHD) WAREHOUSE DATABASE CREATED BY THE MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH. THE PROPOSED RESEARCH AND TRAINING PLAN WILL PROVIDE RIGOROUS EDUCATION IN ADDICTION HEALTH SERVICES RESEARCH, WHICH WILL BE INTEGRATED WITH THE ROBUST CLINICAL TRAINING OF UMASS CHAN MEDICAL SCHOOL AND SUPPORTED THROUGH A MULTIDISCIPLINARY TEAM OF MENTORS WITH SIGNIFICANT EXPERTISE IN IMPLEMENTATION SCIENCE AND OUD RESEARCH IN CRIMINAL-LEGAL SETTINGS. THIS PROPOSAL WILL PROVIDE VALUABLE INSIGHTS INTO STRATEGIES THAT LEAD TO EFFECTIVE AND SUSTAINED MOUD TREATMENT IN JAIL SETTINGS WITH THE GOAL OF INCREASING ACCESSIBILITY TO EVIDENCE-BASED MOUD TREATMENT AND REDUCING OPIOID-RELATED MORTALITY FOR PEOPLE WHO EXPERIENCE INCARCERATION.

Posted 12/27/23, 12:00 AM